[{"id":"33062010-2f9f-457a-bb48-293b21b77b51","acronym":"RAGNAR","url":"https://clinicaltrials.gov/study/NCT04083976","created_at":"2021-01-18T19:59:45.508Z","updated_at":"2025-02-25T12:37:25.290Z","phase":"Phase 2","brief_title":"A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations","source_id_and_acronym":"NCT04083976 - RAGNAR","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGFR2 • FGFR • TACC3 • TACC2","pipe":" | ","alterations":" FGFR3 mutation • FGFR mutation • FGFR fusion","tags":["FGFR2 • FGFR • TACC3 • TACC2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR3 mutation • FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 11/20/2019","start_date":" 11/20/2019","primary_txt":" Primary completion: 12/04/2023","primary_completion_date":" 12/04/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"9c7ac936-fde1-4b07-9296-dad7240ad183","acronym":"","url":"https://clinicaltrials.gov/study/NCT04963153","created_at":"2021-07-15T13:06:11.818Z","updated_at":"2025-02-25T12:28:14.832Z","phase":"Phase 1","brief_title":"Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy","source_id_and_acronym":"NCT04963153","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • FGFR2 • NECTIN4","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • FGFR2 • NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/07/2022","start_date":" 07/07/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-24"},{"id":"0fa68358-5ca0-4783-89e5-388a03a0323e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02421185","created_at":"2021-01-18T11:34:41.906Z","updated_at":"2025-02-25T16:58:47.423Z","phase":"Phase 1/2","brief_title":"Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma","source_id_and_acronym":"NCT02421185","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGF","pipe":"","alterations":" ","tags":["FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 05/25/2015","start_date":" 05/25/2015","primary_txt":" Primary completion: 05/13/2019","primary_completion_date":" 05/13/2019","study_txt":" Completion: 05/16/2019","study_completion_date":" 05/16/2019","last_update_posted":"2025-02-03"},{"id":"25d363db-b73d-42b4-a08a-717568224b15","acronym":"THOR-2","url":"https://clinicaltrials.gov/study/NCT04172675","created_at":"2021-01-18T20:21:16.432Z","updated_at":"2025-02-25T17:00:18.386Z","phase":"Phase 2","brief_title":"A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)","source_id_and_acronym":"NCT04172675 - THOR-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Balversa (erdafitinib) • mitomycin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 02/28/2020","start_date":" 02/28/2020","primary_txt":" Primary completion: 07/12/2024","primary_completion_date":" 07/12/2024","study_txt":" Completion: 03/03/2025","study_completion_date":" 03/03/2025","last_update_posted":"2025-02-03"},{"id":"5c6decd8-2f64-40a9-8da2-299c3dfe4465","acronym":"EAY131-K2","url":"https://clinicaltrials.gov/study/NCT06351371","created_at":"2025-02-27T09:37:17.782Z","updated_at":"2025-02-27T09:37:17.782Z","phase":"Phase 2","brief_title":"Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)","source_id_and_acronym":"NCT06351371 - EAY131-K2","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 07/03/2018","start_date":" 07/03/2018","primary_txt":" Primary completion: 06/02/2022","primary_completion_date":" 06/02/2022","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-10-14"},{"id":"af8ba850-b78d-4d55-8fbd-fbea3bc4dd39","acronym":"EAY131-K1","url":"https://clinicaltrials.gov/study/NCT06308822","created_at":"2025-02-27T09:19:29.964Z","updated_at":"2025-02-27T09:19:29.964Z","phase":"Phase 2","brief_title":"Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)","source_id_and_acronym":"NCT06308822 - EAY131-K1","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/20/2018","start_date":" 08/20/2018","primary_txt":" Primary completion: 07/27/2022","primary_completion_date":" 07/27/2022","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-09-16"},{"id":"04d8f3c7-64bd-44c3-be44-47d8879d4d9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05832892","created_at":"2023-04-27T14:05:02.983Z","updated_at":"2024-07-02T16:34:26.014Z","phase":"Phase 1/2","brief_title":"Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer","source_id_and_acronym":"NCT05832892","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • CTLA4 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CTLA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • erfonrilimab (KN046) • Sulanda (surufatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-14"},{"id":"7d35f15f-f2de-4fad-9cce-09c440f911d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05652283","created_at":"2022-12-15T14:58:15.323Z","updated_at":"2024-07-02T16:35:05.706Z","phase":"Phase 2","brief_title":"Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer","source_id_and_acronym":"NCT05652283","lead_sponsor":"Bai-Rong Xia","biomarkers":" HRD","pipe":"","alterations":" ","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Partruvix (pamiparib) • Sulanda (surufatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/06/2022","start_date":" 11/06/2022","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-05-06"},{"id":"1d4ba0e5-2e91-4eb0-9b78-dcfdf4bea1c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05564416","created_at":"2022-10-03T15:56:45.916Z","updated_at":"2024-07-02T16:35:16.428Z","phase":"Phase 2","brief_title":"Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial","source_id_and_acronym":"NCT05564416","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • FGFR3","pipe":" | ","alterations":" FGFR fusion","tags":["PD-L1 • FGFR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • Balversa (erdafitinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/12/2023","start_date":" 10/12/2023","primary_txt":" Primary completion: 11/03/2023","primary_completion_date":" 11/03/2023","study_txt":" Completion: 11/03/2023","study_completion_date":" 11/03/2023","last_update_posted":"2024-03-05"},{"id":"918ddae7-2ff1-4ee0-9113-6762c5e8dfb2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04579757","created_at":"2021-01-18T21:51:28.003Z","updated_at":"2024-07-02T16:35:19.961Z","phase":"Phase 1/2","brief_title":"Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT04579757","lead_sponsor":"Hutchmed","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Sulanda (surufatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 03/05/2021","start_date":" 03/05/2021","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-02-09"},{"id":"45391173-bfa1-492f-828d-d0cb5112e61f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03238196","created_at":"2021-01-17T17:26:50.151Z","updated_at":"2024-07-02T16:35:21.276Z","phase":"Phase 1","brief_title":"Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer","source_id_and_acronym":"NCT03238196","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" HER-2 • ER • FGFR2 • FGFR1 • FGFR4 • FGF23","pipe":" | ","alterations":" HER-2 negative • FGFR1 amplification • FGFR3 amplification • FGFR4 amplification • FGFR amplification","tags":["HER-2 • ER • FGFR2 • FGFR1 • FGFR4 • FGF23"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • FGFR1 amplification • FGFR3 amplification • FGFR4 amplification • FGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Balversa (erdafitinib) • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/18/2017","start_date":" 08/18/2017","primary_txt":" Primary completion: 04/30/2021","primary_completion_date":" 04/30/2021","study_txt":" Completion: 09/25/2024","study_completion_date":" 09/25/2024","last_update_posted":"2024-02-01"},{"id":"72b6e296-999e-4af6-965d-02f44a6823a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05039892","created_at":"2021-09-10T16:57:16.515Z","updated_at":"2024-07-02T16:35:21.555Z","phase":"Phase 2","brief_title":"Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma","source_id_and_acronym":"NCT05039892","lead_sponsor":"3D Medicines (Beijing) Co., Ltd.","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e segigratinib (3D185)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-01-31"},{"id":"2a648675-5366-434b-9eca-31ea418b2eb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00355238","created_at":"2021-01-18T01:13:50.252Z","updated_at":"2024-07-02T16:35:27.336Z","phase":"Phase 2","brief_title":"A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer","source_id_and_acronym":"NCT00355238","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brivanib alaninate (BMS-582664)"],"overall_status":"Completed","enrollment":" Enrollment 137","initiation":"Initiation: 12/31/2006","start_date":" 12/31/2006","primary_txt":" Primary completion: 04/30/2010","primary_completion_date":" 04/30/2010","study_txt":" Completion: 04/30/2010","study_completion_date":" 04/30/2010","last_update_posted":"2023-12-01"},{"id":"01d93d84-ceb8-4d89-9e96-016cb7325fdc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05481463","created_at":"2022-08-01T15:55:26.976Z","updated_at":"2024-07-02T16:35:29.397Z","phase":"Phase 2","brief_title":"Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer","source_id_and_acronym":"NCT05481463","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lonsurf (trifluridine/tipiracil) • Sulanda (surufatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/28/2022","start_date":" 03/28/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-11-13"},{"id":"e0240271-2ac4-47c2-9956-8f3eec7a44d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00640471","created_at":"2021-01-18T02:22:59.928Z","updated_at":"2024-07-02T16:35:40.878Z","phase":"Phase 3","brief_title":"Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer","source_id_and_acronym":"NCT00640471","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" RAS wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • brivanib alaninate (BMS-582664)"],"overall_status":"Completed","enrollment":" Enrollment 750","initiation":"Initiation: 05/12/2008","start_date":" 05/12/2008","primary_txt":" Primary completion: 09/06/2011","primary_completion_date":" 09/06/2011","study_txt":" Completion: 01/10/2013","study_completion_date":" 01/10/2013","last_update_posted":"2023-08-04"},{"id":"1e30bc94-6063-438f-88ab-1406ca5f477b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04653480","created_at":"2021-01-19T20:41:06.787Z","updated_at":"2024-07-02T16:35:42.871Z","phase":"Phase 2","brief_title":"Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC","source_id_and_acronym":"NCT04653480","lead_sponsor":"Zhejiang University","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • RAS mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • oxaliplatin • irinotecan • Sulanda (surufatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 02/01/2021","start_date":" 02/01/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-07-17"},{"id":"913fa15c-9288-4cf0-a89a-f0851bfabf86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04353375","created_at":"2023-07-06T20:09:42.965Z","updated_at":"2025-02-25T14:51:46.214Z","phase":"Phase 2","brief_title":"Phase 2 Study of HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma","source_id_and_acronym":"NCT04353375","lead_sponsor":"Hutchmed","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fanregratinib (HMPL-453)"],"overall_status":"Recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 09/03/2020","start_date":" 09/03/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-07-06"},{"id":"a918b622-1695-4ae4-8aaf-74e22d538627","acronym":"","url":"https://clinicaltrials.gov/study/NCT05746728","created_at":"2023-02-28T13:01:14.764Z","updated_at":"2024-07-02T16:35:51.316Z","phase":"Phase 1/2","brief_title":"Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer","source_id_and_acronym":"NCT05746728","lead_sponsor":"Huihua Xiong","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2","pipe":" | ","alterations":" HER-2 expression • ER expression • PARP1 mutation","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • ER expression • PARP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Sulanda (surufatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-04-06"},{"id":"98d97099-58b6-42c8-a565-6a53ad427d4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05186545","created_at":"2022-01-11T15:56:04.181Z","updated_at":"2024-07-02T16:36:04.549Z","phase":"Phase 2","brief_title":"An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer","source_id_and_acronym":"NCT05186545","lead_sponsor":"The First Affiliated Hospital of Zhengzhou University","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Epidaza (chidamide) • Sulanda (surufatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2022-09-02"},{"id":"ea39bf9b-3a98-46eb-8bfc-59230c1a4e1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05395780","created_at":"2022-05-27T11:56:31.465Z","updated_at":"2024-07-02T16:36:09.466Z","phase":"Phase 2","brief_title":"A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT05395780","lead_sponsor":"Maxinovel Pty., Ltd.","biomarkers":" FGFR1OP2","pipe":" | ","alterations":" FGFR1 expression","tags":["FGFR1OP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Max-40279"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-06-02"},{"id":"c7c7b388-a345-4c9d-9046-42dc16d8c6a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05369286","created_at":"2022-05-11T16:55:50.518Z","updated_at":"2024-07-02T16:36:10.590Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05369286","lead_sponsor":"Maxinovel Pty., Ltd.","biomarkers":" FGFR1OP2","pipe":" | ","alterations":" FGFR1 expression","tags":["FGFR1OP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Max-40279"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 08/31/2023","study_completion_date":" 08/31/2023","last_update_posted":"2022-05-11"},{"id":"d4d894ac-2658-4499-8ad7-5be03852e67a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05173142","created_at":"2021-12-29T13:53:45.797Z","updated_at":"2025-02-25T14:52:10.343Z","phase":"Phase 1/2","brief_title":"HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors","source_id_and_acronym":"NCT05173142","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" FGFR","pipe":" | ","alterations":" PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • docetaxel • Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr) • fanregratinib (HMPL-453)"],"overall_status":"Recruiting","enrollment":" Enrollment 141","initiation":"Initiation: 01/22/2022","start_date":" 01/22/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2022-03-08"},{"id":"b185f5af-b20b-432d-b8f0-d2a61b2a09b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03412292","created_at":"2021-01-18T16:50:05.305Z","updated_at":"2024-07-02T16:36:18.334Z","phase":"Phase 1","brief_title":"MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)","source_id_and_acronym":"NCT03412292","lead_sponsor":"Maxinovel Pty., Ltd.","biomarkers":" FLT3 • FGFR","pipe":" | ","alterations":" FLT3 wild-type","tags":["FLT3 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Max-40279"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2018","start_date":" 08/01/2018","primary_txt":" Primary completion: 11/01/2022","primary_completion_date":" 11/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-01-19"},{"id":"785cf943-f46d-41b5-a744-2198e88473ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05165407","created_at":"2021-12-21T15:53:36.458Z","updated_at":"2024-07-02T16:36:19.281Z","phase":"Phase 2","brief_title":"Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC","source_id_and_acronym":"NCT05165407","lead_sponsor":"Peking University","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Sulanda (surufatinib) • Tabosun (ipilimumab N01 injection)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2021-12-21"}]